The Protocol Review and Monitoring System (PRMS) oversees and ensures the prioritization, feasibility, scientific merit and progress of all clinical studies at the Cancer Therapy and Research Center (CTRC). The PRMS consists of three components that work in collaboration with one another to ensure that the right trials for the right population with the right resources open and accrue. This occurs via each of the committee's prioritization, feasibility, scientific review and progress in the selection and activation of all trials at CTRC. The PRMS evaluation process occurs prior to submission to submission to the UTHSCSA Institutional Review Board (IRB) and is required for IRB approval. The PRMS process is complementary to the IRB review and does not overlap or duplicate the responsibilities of the IRB. The IRB will not approve a protocol without the PRC's approval. Protocols are initially discussed in Clinical Disease Site Teams (CDST) teams where they receive priority scoring. Operations and Logistics Committee (O&L) where they are reviewed for feasibility, and then the Protocol Review Committee (PRC) where they receive data safety and monitoring, scientific and biostatistical reviews. After a study has opened to accrual, the PRC provides ongoing review to ensure adequate accrual and scientific progress. The PRC has the authority to close studies that have not progressed toward their intended scientific objectives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-20
Application #
8758431
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
1997-08-01
Project End
2019-07-31
Budget Start
2014-09-16
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$77,682
Indirect Cost
$39,732
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Wei, Zhen; Panneerdoss, Subbarayalu; Timilsina, Santosh et al. (2018) Topological Characterization of Human and Mouse m5C Epitranscriptome Revealed by Bisulfite Sequencing. Int J Genomics 2018:1351964
Deng, Yilun; Qin, Yuejuan; Srikantan, Subramanya et al. (2018) The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex. Hum Mol Genet 27:1794-1808
Zanotto-Filho, Alfeu; Rajamanickam, Subapriya; Loranc, Eva et al. (2018) Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Lett 425:101-115
Chiang, Huai-Chin; Zhang, Xiaowen; Zhao, Xiayan et al. (2018) Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development. Sci Rep 8:2731
Donegan, Jennifer J; Boley, Angela M; Lodge, Daniel J (2018) Embryonic stem cell transplants as a therapeutic strategy in a rodent model of autism. Neuropsychopharmacology 43:1789-1798
Segovia, Jesus A; Chang, Te-Hung; Winter, Vicki T et al. (2018) NLRP3 Is a Critical Regulator of Inflammation and Innate Immune Cell Response during Mycoplasma pneumoniae Infection. Infect Immun 86:
Cepeda, Sergio; Cantu, Carolina; Orozco, Stephanie et al. (2018) Age-Associated Decline in Thymic B Cell Expression of Aire and Aire-Dependent Self-Antigens. Cell Rep 22:1276-1287
Vaidya, Anand; Flores, Shahida K; Cheng, Zi-Ming et al. (2018) EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. N Engl J Med 378:1259-1261
Ramasamy, Kumaraguruparan; Balasubramanian, Sowmya; Manickam, Krishnan et al. (2018) Mycoplasma pneumoniae Community-Acquired Respiratory Distress Syndrome Toxin Uses a Novel KELED Sequence for Retrograde Transport and Subsequent Cytotoxicity. MBio 9:
Snead, Wilton T; Zeno, Wade F; Kago, Grace et al. (2018) BAR scaffolds drive membrane fission by crowding disordered domains. J Cell Biol :

Showing the most recent 10 out of 989 publications